{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-007826","form_type":"8-K","ticker":"MXCT","cik":"0001287098","company_name":"MAXCYTE, INC.","filed_at":"2022-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.090977+00:00","generated_at":"2026-06-25T22:16:09.282751+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MaxCyte Q1 revenue $11.6M (+78% YoY); raises 2022 core revenue guidance to at least 25%","bullets":["Total revenue $11.6M, up 78% YoY; core business revenue $9.6M, up 48% YoY driven by cell therapy customers (+57%).","SPL Program-related revenue $2.0M vs immaterial; total SPLs now 16 with Intima Bioscience addition.","Net loss narrowed to $4.1M from $7.1M; EBITDA loss $3.7M vs $6.4M.","Raises 2022 core revenue guidance to at least 25% growth; reiterates SPL milestone revenue ~$4M.","Cash and investments $246.3M as of March 31, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-007826","json":"https://secwatch.observer/filing/0001558370-22-007826.json","markdown":"https://secwatch.observer/filing/0001558370-22-007826.md","text":"https://secwatch.observer/filing/0001558370-22-007826.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1287098/000155837022007826/0001558370-22-007826-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1287098/000155837022007826/mxct-20220509x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T22:16:09.282751+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}